Sana Biotechnology (SANA) Income from Continuing Operations (2020 - 2026)
Sana Biotechnology (SANA) reported Income from Continuing Operations of 162416000.0 for Q1 2026, up 25.17% on a YoY basis from 129761206.43 in Q1 2025, and down 165.42% sequentially from 61193000.0 in Q4 2025.
Sana Biotechnology (SANA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Sana Biotechnology (SANA) has 7 years of Income from Continuing Operations data on file, last reported at 162416000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 25.17% year-over-year to 162416000.0; the trailing twelve-month figure through Mar 2026 stood at 534943000.0 (up 16.4% YoY), and the FY2025 full-year result was 369637000.0, down 5.54% from the prior year.
- Income from Continuing Operations retreated to 162416000.0 in Q1 2026, from 61193000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 52381000.0 in Q4 2024 to a low of 493136000.0 in Q4 2023.
- A 5-year average of 193890058.82 and a median of 196659000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations tumbled 773.18% in 2022 and surged 89.38% in 2024, its largest moves.
- Tracing SANA's Income from Continuing Operations over 5 years: stood at 83412000.0 in 2022, then sank by 491.21% to 493136000.0 in 2023, then surged by 89.38% to 52381000.0 in 2024, then fell by 16.82% to 61193000.0 in 2025, then slumped by 165.42% to 162416000.0 in 2026.
- Business Quant data shows SANA's Income from Continuing Operations at 162416000.0 in Q1 2026, 61193000.0 in Q4 2025, and 86080000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Sana Biotechnology | 888.71 Mn | 888.71 Mn | - | -162.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -162.42 Mn |
| Dec 31, 2025 | -61.19 Mn |
| Sep 30, 2025 | -86.08 Mn |
| Jun 30, 2025 | -225.25 Mn |
| Mar 31, 2025 | -217.03 Mn |
| Dec 31, 2024 | -52.38 Mn |
| Sep 30, 2024 | -238.12 Mn |
| Jun 30, 2024 | -132.38 Mn |
| Mar 31, 2024 | -196.66 Mn |
| Dec 31, 2023 | -493.14 Mn |
| Sep 30, 2023 | -209.07 Mn |
| Jun 30, 2023 | -351.07 Mn |
| Mar 31, 2023 | -188.49 Mn |
| Dec 31, 2022 | -83.41 Mn |
| Sep 30, 2022 | -241.01 Mn |
| Jun 30, 2022 | -142.88 Mn |
| Mar 31, 2022 | -215.55 Mn |
| Dec 31, 2021 | -269.19 Mn |
| Sep 30, 2021 | -254.38 Mn |
| Jun 30, 2021 | -16.36 Mn |